全文获取类型
收费全文 | 3303篇 |
免费 | 249篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 93篇 |
妇产科学 | 75篇 |
基础医学 | 398篇 |
口腔科学 | 147篇 |
临床医学 | 252篇 |
内科学 | 827篇 |
皮肤病学 | 41篇 |
神经病学 | 429篇 |
特种医学 | 79篇 |
外科学 | 415篇 |
综合类 | 28篇 |
预防医学 | 167篇 |
眼科学 | 113篇 |
药学 | 171篇 |
中国医学 | 4篇 |
肿瘤学 | 221篇 |
出版年
2023年 | 27篇 |
2022年 | 55篇 |
2021年 | 124篇 |
2020年 | 73篇 |
2019年 | 76篇 |
2018年 | 102篇 |
2017年 | 72篇 |
2016年 | 79篇 |
2015年 | 96篇 |
2014年 | 132篇 |
2013年 | 162篇 |
2012年 | 211篇 |
2011年 | 237篇 |
2010年 | 116篇 |
2009年 | 140篇 |
2008年 | 212篇 |
2007年 | 203篇 |
2006年 | 175篇 |
2005年 | 162篇 |
2004年 | 142篇 |
2003年 | 132篇 |
2002年 | 120篇 |
2001年 | 30篇 |
2000年 | 23篇 |
1999年 | 39篇 |
1998年 | 27篇 |
1997年 | 15篇 |
1996年 | 15篇 |
1995年 | 22篇 |
1994年 | 19篇 |
1992年 | 29篇 |
1991年 | 21篇 |
1990年 | 25篇 |
1989年 | 20篇 |
1988年 | 27篇 |
1987年 | 28篇 |
1986年 | 22篇 |
1985年 | 22篇 |
1984年 | 20篇 |
1983年 | 15篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1979年 | 23篇 |
1978年 | 22篇 |
1976年 | 17篇 |
1975年 | 24篇 |
1974年 | 21篇 |
1973年 | 19篇 |
1970年 | 21篇 |
1969年 | 13篇 |
排序方式: 共有3558条查询结果,搜索用时 15 毫秒
31.
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. 总被引:4,自引:0,他引:4
John P Leonard Morton Coleman Lale Kostakoglu Amy Chadburn Ethel Cesarman Richard R Furman Michael W Schuster Ruben Niesvizky Daniel Muss Jennifer Fiore Stewart Kroll George Tidmarsh Shankar Vallabhajosula Stanley J Goldsmith 《Journal of clinical oncology》2005,23(24):5696-5704
PURPOSE: To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma. PATIENTS AND METHODS: Thirty-five patients received an abbreviated course (three cycles) of fludarabine followed 6 to 8 weeks later by tositumomab and iodine I 131 tositumomab. RESULTS: After fludarabine, 31 (89%) of 35 patients responded, with three (9%) of 31 patients achieving a complete response (CR). After the full regimen of fludarabine and iodine I 131 tositumomab, all 35 patients responded; 30 (86%) of 35 patients achieved CR, and five (14%) of 35 achieved partial response. After a median follow-up of 58 months, the median progression-free survival (PFS) had not been reached (95% CI, 27 months to not reached), but it will be at least 48 months. The 5-year estimated PFS rate is 60%. Baseline Follicular Lymphoma International Prognostic Index (FLIPI) was significantly associated (P = .003) with PFS. Five of six patients with more than 25% bone marrow involvement at baseline achieved adequate bone marrow cytoreduction to receive standard-dose iodine I 131 tositumomab. Ten (77%) of 13 patients with baseline bone marrow Bcl-2 positivity demonstrated molecular remissions at month 12. Toxicities were manageable and principally hematologic. Two (6%) of 35 patients developed human antimurine antibodies (HAMA) after RIT. CONCLUSION: Use of abbreviated fludarabine before iodine I 131 tositumomab can reduce bone marrow involvement, when needed, to allow the use of RIT and can suppress HAMA responses. This sequential treatment regimen is highly effective as front-line therapy for follicular lymphoma, particularly for low- or intermediate-risk FLIPI patients. 相似文献
32.
33.
Mamo Gebrezgiabher Sren Schlittenhardt Cyril Rajnk Juraj Kuchr Assefa Sergawie Juraj ernk Mario Ruben Madhu Thomas Roman Bo
a 《RSC advances》2022,12(33):21674
The triangulo-{Er3} complex [Er3Cl(o-van)3(OH)2(H2O)5]Cl3·nH2O (n = 9.4; H(o-van) = o-vanillin) (1) was generated by an in situ method. The isolated Er(iii) complex 1 was characterized by elemental analysis and molecular spectroscopy. The results of single crystal X-ray diffraction studies have shown that 1 is built up of trinuclear [Er3Cl(o-van)3(OH)2(H2O)5]3+ complex cations, chloride anions and water solvate molecules. Within the complex cation the three Er(iii) central atoms are placed at the apexes of a triangle which are bridged by three (o-van)− ligands with additional chelating functions and two μ3-OH− ligands. Additionally five aqua and one chlorido ligands complete the octa-coordination of the three Er(iii) atoms. AC susceptibility measurements reveal that the compound exhibits slow magnetic relaxation with two relaxation modes.The triangulo-{Er3} complex [Er3Cl(o-van)3(OH)2(H2O)5]Cl3·nH2O (n = 9.4; H(o-van) = o-vanillin) (1) was generated by an in situ method. 相似文献
34.
35.
36.
Bruno Ribeiro Ruben Offoiach Stefano Rossetti Elisa Salatin Maria Lekka Lorenzo Fedrizzi 《Materials》2022,15(9)
Anodic oxidation of CP-Ti, for production of TiO2 nanotubes, has been extensively described in terms of the electrochemical mechanism of tubular growth or the effect of the parameters on the final tube morphology. Recently, a kinetic growth model was proposed to describe the distinct morphologies of the anodic oxide layer as phases of the nanotubular development process, offering a new perspective for the tuning of nanotube production. In this work, the anodizing behavior of a CP-Ti alloy in an ethylene glycol electrolyte was investigated in light of this new model. The final morphology of the nanotubes was characterized by SEM, considering the effects of electrolyte aging, the microstructure, the applied potential difference and time on the morphological development of nanotubes. Electrolyte aging was shown to lead to a decreased dissolution effect on the oxide. The applied potential difference was shown to lead to an increased dissolution effect and more rapid nanotube growth kinetics, while time resulted in extended dissolution. Moreover, the obtained results were analyzed considering a previous study focused on the anodizing behavior of the α- and β-phases of Ti6Al4V alloy. Overall, the tube morphology resembled that obtained for the Al-containing α-phase of the Ti6Al4V alloy, but the growth kinetics were considerably slower on CP-Ti. 相似文献
37.
Shane AL Cabana MD Vidry S Merenstein D Hummelen R Ellis CL Heimbach JT Hempel S Lynch SV Sanders ME Tancredi DJ 《Gut microbes》2010,1(4):243-253
The heterogeneity of human clinical trials to assess the effectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the effectiveness of probiotics would be beneficial. Furthermore, the reporting, presentation and communication of results may also affect the validity of the scientific evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are offered along with recommendations for enhanced collaboration to advance research in this emerging field. 相似文献
38.
Petros C Karakousis Frangiscos G Sifakis Ruben Montes de Oca Valerianna C Amorosa Kathleen R Page Yukari C Manabe James D Campbell 《BMC infectious diseases》2007,7(1):89
Background
The ability of medical residents training at U.S. urban medical centers to diagnose and manage tuberculosis cases has important public health implications. We assessed medical resident knowledge about tuberculosis diagnosis and early management based on American Thoracic Society guidelines. 相似文献39.
40.
Rafic Zaitoun Gerald Dorros Sriram S. Iyer Ruben F. Lewin 《Catheterization and cardiovascular interventions》1990,20(4):254-256
This case report describes the feasibility and potential benefit of the use of a high-speed rotational atherectomy device (the Rotablator?) in the treatment of renovascular hypertension in a patient with a recorded restenosis of an ostial renal artery lesion following standard balloon angioplasty. 相似文献